Journal of Clinical Pediatrics and Neonatal Care

News about Emollients with Rhealba Oat Plantlets Extract: Prevention and Treatment of Atopic Dermatitis

Published on: 2018-09-23


Atopic dermatitis (AD) is a common chronic inflammatory skin disease which has negative socioeconomic consequences. At the bottom of the AD therapeutic pyramid, the emollient strategy has been set up. It seems that all profits and success in terms of efficacy of the basic emollient therapy has been proven not only in relation to the control of the AD signs and symptoms but also in terms of their prophylactic, highly important effect in both primary and secondary prevention. Some clinical studies have already demonstrated that emollients containing Rhealba Oat plantlets extract, enriched with the Biovect system, counteract two fundamental factors responsible for the development of AD: they reconstruct the epidermal barrier and have an anti-inflammatory effect. In addition, they are free from proteins that could potentially lead to transcutaneous sensitisation causing classical allergic reactions. This study was set up to assess the tolerance of an emollient based on Rhealba Oat plantlets extract in newborns at risk to develop Atopic Dermatitis. Investigators considered that the three textures were very well tolerated by newborns at risk to develop Atopic Dermatitis. In consequence emollients based on Rhealba Oat plantlets extract are best suited for people with Atopic Dermatitis or at risk to develop one, from birth to adulthood. Clinical proofs obtained through multiple studies, performed in all age groups, support this statement.


Newborns; Atopic Dermatitis; tolerance;dermatology; emollient; Rhealba Oat plantlets extract